BPN programs have launched a series of collaborative drug discovery and development projects focused on supporting preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain and other neurological disorders. These projects are developing therapeutic candidates through an iterative process of lead optimization, in vitro and in vivo testing. A component of this process is the conduct of in vivo maximum tolerated dose (MTD) and dose-range finding (DRF) toxicity assessment of compounds. This task order is non-rodent (MTD) and DRF studies of a compound generated by BPN Program.